HBK Investments’s Ascendis Pharma A/S ASND Stock Holding History

HBK Investments’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-7,035	Closed	-$828K	–	628
2019 Q1	$828K	Buy	+7,035	New	+$616K	0.01%	721
2018 Q4	–	Sell	-7,174	Closed	-$508K	–	1186
2018 Q3	$508K	Buy	+7,174	New	+$494K	﹤0.01%	931
2017 Q4	–	Sell	-35,000	Closed	-$1.27M	–	971
2017 Q3	$1.27M	Buy	+35,000	New	+$1M	0.01%	566

Other funds holding ASND

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments's ASND Position: Q2 2019 in Review

HBK Investments sold out of Ascendis Pharma A/S (ASND) in Q2 2019, closing a stake of 7,035 shares — an estimated $828K sold.

HBK Investments first reported a position in ASND in Q3 2017 and held it in 3 quarters. The position peaked at $1.27M in Q3 2017. 132 funds tracked by Wall St. Rank hold ASND as of Q2 2019.

HBK Investments reported no remaining Ascendis Pharma A/S position as of Q2 2019 after selling out during the quarter.
HBK Investments sold 7,035 Ascendis Pharma A/S shares in Q2 2019, an estimated $828K.
HBK Investments first reported a position in Ascendis Pharma A/S in Q3 2017 and held it in 3 quarters.
HBK Investments's Ascendis Pharma A/S position peaked at $1.27M in Q3 2017.
132 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2019.

Based on HBK Investments's 13F filing for Q2 2019, filed 14 Aug 2019.